In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
Navigating private equity in health care amid regulatory scrutiny
She joined Leslie C. Overton from Axinn Veltrop & Harkrider LLP and Rebekah Goshorn Jurata of the American Investment Council to discuss the growing antitrust...